A clinical trial has been conducted using long peptide vaccines targeting KRAS p.G12D/R mutations in 20 PDAC and 5 CRC patients, where 84% exhibited specific T cell responses to KRAS p.G12D/R and observed tumor biomarker responses [132]. The gene discussed is KRAS; the disease is neoplasm.